S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Eli Lilly and Company (LLY) Stock Price, News & Analysis

$751.20
-0.44 (-0.06%)
(As of 04/15/2024 ET)
Today's Range
$749.52
$768.00
50-Day Range
$705.01
$792.28
52-Week Range
$367.35
$800.78
Volume
2.36 million shs
Average Volume
3.09 million shs
Market Capitalization
$713.76 billion
P/E Ratio
129.52
Dividend Yield
0.69%
Price Target
$728.05

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.84 Rating Score
Upside/​Downside
3.1% Downside
$728.05 Price Target
Short Interest
Healthy
0.64% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.57mentions of Eli Lilly and Company in the last 14 days
Based on 53 Articles This Week
Insider Trading
Selling Shares
$86.54 M Sold Last Quarter
Proj. Earnings Growth
47.43%
From $12.46 to $18.37 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.83 out of 5 stars

Medical Sector

34th out of 929 stocks

Pharmaceutical Preparations Industry

14th out of 424 stocks

LLY stock logo

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Stock Price History

LLY Stock News Headlines

Novo Nordisk Arms Wegovy to Be a Triple Threat (LLY)
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? (LLY)
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs? (LLY)
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill (LLY)
Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher
DexCom Stock Gains from GLP-1 Diabetic Users (LLY)
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
7 Stocks That Will Drive the Weight Loss Drugs Market (LLY)
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (LLY)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
LifeMD Shares Come Back to Life on GLP-1 Business Growth (LLY)
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Eli Lilly and Company (NYSE:LLY) Shares Down 0.3%
How to Invest in Eli Lilly (LLY)
See More Headlines
Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2024
Ex-Dividend for 3/8 Dividend
2/14/2024
Dividend Payable
3/08/2024
Today
4/15/2024
Next Earnings (Confirmed)
4/30/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
53245710
Employees
43,000
Year Founded
1876

Price Target and Rating

Average Stock Price Target
$728.05
High Stock Price Target
$1,000.00
Low Stock Price Target
$458.00
Potential Upside/Downside
-3.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.84
Research Coverage
19 Analysts

Profitability

Net Income
$5.24 billion
Pretax Margin
19.21%

Debt

Sales & Book Value

Annual Sales
$34.12 billion
Cash Flow
$7.62 per share
Book Value
$11.44 per share

Miscellaneous

Free Float
948,929,000
Market Cap
$713.76 billion
Optionable
Optionable
Beta
0.34

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

  • Eli Lilly and Company offers a diverse range of pharmaceutical products including Humalog U-100, Humalog U-200, and Trulicity, catering to various medical needs.
  • Recent insider transactions indicate confidence in the company's future, with major shareholder Lilly Endowment Inc selling shares at a significant value, suggesting positive outlook.
  • Wall Street analysts have provided optimistic growth forecasts for Eli Lilly and Company, with price targets being raised by reputable firms like JPMorgan Chase & Co., indicating strong potential for stock appreciation.
  • The company's stock price has shown an upward trend, with analysts projecting further growth potential, making it an attractive investment opportunity.
  • Eli Lilly and Company's consistent focus on research and development to introduce innovative pharmaceutical solutions positions it well for sustained growth in the healthcare sector.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

  • Despite positive growth forecasts, there may be market volatility affecting the stock price, leading to potential short-term fluctuations in investment returns.
  • Increased competition in the pharmaceutical industry could impact Eli Lilly and Company's market share and profitability, posing a risk to investor returns.
  • Regulatory changes or challenges in the healthcare sector could affect the company's operations and financial performance, influencing investor confidence.
  • Dependency on a few key products like Trulicity for revenue generation may expose the company to risks associated with product concentration, impacting investor sentiment.
  • Market uncertainties and macroeconomic factors could influence the demand for pharmaceutical products, affecting Eli Lilly and Company's revenue streams and stock performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 11, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

LLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings
or view top-rated stocks.

What is Eli Lilly and Company's stock price target for 2024?

19 brokerages have issued twelve-month target prices for Eli Lilly and Company's shares. Their LLY share price targets range from $458.00 to $1,000.00. On average, they expect the company's stock price to reach $728.05 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts price targets for LLY
or view top-rated stocks among Wall Street analysts.

How have LLY shares performed in 2024?

Eli Lilly and Company's stock was trading at $582.92 at the start of the year. Since then, LLY stock has increased by 28.9% and is now trading at $751.20.
View the best growth stocks for 2024 here
.

Are investors shorting Eli Lilly and Company?

Eli Lilly and Company saw a increase in short interest in February. As of February 29th, there was short interest totaling 5,420,000 shares, an increase of 5.2% from the February 14th total of 5,150,000 shares. Based on an average trading volume of 3,280,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.6% of the company's stock are sold short.
View Eli Lilly and Company's Short Interest
.

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our LLY earnings forecast
.

How can I listen to Eli Lilly and Company's earnings call?

Eli Lilly and Company will be holding an earnings conference call on Tuesday, April 30th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Tuesday, February, 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The business earned $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 51.22% and a net margin of 15.36%. Eli Lilly and Company's quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.09 earnings per share.
Read the conference call transcript
.

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Friday, December 8th. Investors of record on Thursday, February 15th will be paid a dividend of $1.30 per share on Friday, March 8th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Wednesday, February 14th. This is a positive change from the stock's previous quarterly dividend of $1.13.
Read our dividend analysis for LLY
.

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $5.20 per share and currently has a dividend yield of 0.69%. The company has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 89.66%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 28.31% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company issued an update on its FY24 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of $12.20-12.70 for the period, compared to the consensus estimate of $12.39. The company issued revenue guidance of $40.4-41.6 billion, compared to the consensus revenue estimate of $39.27 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.05%), Global Assets Advisory LLC (0.04%), Sarasin & Partners LLP (0.03%), Congress Asset Management Co. MA (0.02%), Cardano Risk Management B.V. (0.02%) and Gateway Investment Advisers LLC (0.02%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends
.

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Eli Lilly and Company have any subsidiaries?
The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
This page (NYSE:LLY) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners